Kiniksa CEO/Chairman Patel Notices $51.6M Sale, Largest of Four Officer 144s
KNSA has more than doubled off its 52-week low of $36.56 on elevated volume (2.1× avg).
Summary
Kiniksa's CEO/Chairman noticed a sale of 553,794 shares (~$51.6M) under a pre-existing 10b5-1 plan, the largest of four officer Form 144s filed the same evening after a strong Q3 and guidance raise.
Key Events · Ownership and Investor Activity · KNSA
-
CEO Notices $51.6M Share Sale
Sanj K Patel, Officer and Director, noticed the sale of 553,794 Class A shares with an aggregate market value of $51,571,367, brokered through Charles Schwab.
-
Mostly Option Exercise and Founder Shares
377,000 shares came from an employee stock option exercise on 10/30/2026 paid via broker cashless exercise, 125,000 are 2015 founder shares and 51,794 are restricted stock lapses.
-
Pre-Planned 10b5-1 Sale
The 10b5-1 plan was adopted 07/30/2026 and the filing reports no securities sold in the prior three months; options may be sold over various dates.
-
Fourth Officer 144 of the Evening
Follows concurrent notices from Paolini (~$8.9M), Megna (~$4.6M) and President/COO Ross Moat (~$9.75M), a cluster of insider distribution after the Q3 beat and Arcalyst guidance raise to $1.045B-$1.05B.
Analysis · KNSA · Life Sciences
Why it matters: Sanj Patel, CEO and Chairman, has filed notice to sell 553,794 Class A shares worth about $51.6M — roughly 1.1% of the 48.8M shares outstanding and the biggest of four officer sale notices filed the same evening (Paolini ~$8.9M, Megna ~$4.6M, Moat ~$9.75M). Most of the shares come from a cashless option exercise and 2015 founder shares, and the sale runs under a 10b5-1 plan adopted July 30, 2026, so it is pre-scheduled rather than a reaction to the Q3 beat and Arcalyst guidance raise on October 27. The volume matters more than the plan label: four officers notching sales within minutes of each other is a cluster of insider distribution into strength, and the market will read it as such even though no shares have been sold yet.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.5% of the 1545 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KNSA was trading at $92.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $36.56 to $98.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.